AIDS Vaccines

HIV Envelope Elicits Natural Neutralizing Antibodies

Published in Vaccine Weekly, November 30th, 1998

If the virus can do it, why can't a vaccine'

Some sera from HIV infected individuals contain potent antibodies capable of neutralizing both wild-type and T-cell-line-adapted (TCLA) HIV-1 strains. But recipients of HIV vaccines made from the HIV gp120 envelope glycoprotein do not exhibit such strong responses.

Do the vaccines have the wrong antigen' Not according to a series of studies by Walter Reed Army Institute researchers Nicholas M. Stamatos and Thomas C. VanCott and colleagues.

Stamatos et al. found that patient sera with strong neutralizing antibody activity contains potent anti-envelope antibodies capable of virus...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1998-11-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry